Entities / Company
Incyte.
American pharmaceutical company
- Reports this week
- 0
- Active events
- 2
- Connections
- 133
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
Earlier this month
-
Syndax Pharmaceuticals reported collaboration revenue derived from Niktimvo sales.Well supported5 reports
-
Competitors Agios Pharmaceuticals and Incyte are being compared based on their financial metrics.Some support2 reports
-
Incyte, a biotech company based in Wilmington, outperformed the biotech ETF.Some support2 reports
-
Incyte is presenting data at the European Academy of Dermatology and Venereology (EADV) conference held in Vienna.Some support1 report
-
GSK, Incyte, Vertex, and Janssen announced new collaboration agreements with Halozyme on September 21, 2026.Some support1 report
-
FDA review extended for ruxolitinib cream, while Incyte benefits from potential Trump-era tariffs, leading to analyst upgrades and recommendations.Some support6 reports
-
MarketBeat provided analyst recommendations for Incyte on September 20, 2026.Some support1 report
One to three months ago
-
Dr. Iyengar gained experience during his tenure, involving companies such as Incyte, Novartis, and McKinsey & Company.Some support1 report
-
Incyte stock is trading on the Nasdaq exchange, with its performance being discussed in a bullish light due to strong fundamentals and earnings momentum.Some support2 reports
-
Wellington Management reduced its stock holdings in Incyte, alongside sales by EVP Patrick Mayes and insider Pablo Cagnoni.Some support1 report
-
FDA approved Rasonque for metastatic PDAC, while Kras and Incyte also developed PDAC inhibitors and Incyte received a CMS settlement benefit.Some support2 reports
-
Knight's affiliate submitted an application to ANVISA and secured exclusive distribution rights for Incyte's tafasitamab.Some support3 reports
-
TD Cowen upgraded shares of Incyte to strong-buy rating and adjusted price targets on August 25, 2026.Some support1 report
-
AbbVie, Incyte, and Biogen are noted as peers in the biotechnology segment after reporting their Q2 financial results.Some support2 reports
-
Incyte received a one-time accounting benefit from a CMS settlement.Some support1 report
-
Citigroup provided a market rating on Incyte stock.Some support1 report
-
Norges Bank purchased a new stake in Incyte, while RBC and TD Cowen provided stock rating updates on July 21, 2026.Some support1 report
Gone quiet
No new reports in 90+ days-
Governor Matt Meyer launched an initiative in Dover, which involved grant agreement reductions that subsequently freed up funds for the state of Delaware.Some support1 report
-
Incyte filed required share ownership disclosure documents with the Securities and Exchange Commission on July 14, 2026.Some support4 reports
-
Biotech M&A speculation involving Incyte, AbbVie, and Viking Therapeutics, with three Nasdaq-listed names under watch.Some support1 report1 development inside
-
Incyte acquired Vega Therapeutics to diversify its late-stage pipeline.Some support1 report
-
TD Cowen, Royal Bank of Canada, and Oppenheimer Holdings reaffirmed ratings and raised price targets for Incyte stock.Some support1 report
-
Sino Biopharmaceutical Limited and Incyte are both classified as large-cap medical companies.Some support2 reports
-
The European Medicines Agency is seeking a positive opinion on ruxolitinib cream, with final approval resting with the executive branch.Some support2 reports
-
FDA accepted NDA for zilurgisertib in FOP, following collaboration on the PROGRESS study between Mirum Pharmaceuticals and Incyte.Some support2 reports
-
Stifel reiterated a Buy rating on Incyte.Some support1 report
-
Incyte was required to file 13F filings with the SEC on June 6, 2026.Some support1 report
-
Incyte appointed Bill Meury as the new CEO on June 27, 2025, causing the company's stock to rise.Speculative2 reports
-
Bristol Myers Squibb and Incyte pioneered novel therapies for anal cancer.Some support1 report
-
Incyte granted equity awards to Asia, tied to relative total shareholder return, on August 28, 2025.Some support1 report
-
The FDA approved Niktimvo, Trump pledged benefits for oil and gas stocks, and several companies reported new HR hires.Some support2 reports1 development inside
-
Incyte and Gilead Sciences are discussed in the context of commercializing innovative medicines for life-threatening diseases.Some support2 reports
-
Incyte's Opzelura received approval in the United States on June 23, 2025, and the FDA extended the review for the company's sNDA.Speculative2 reports
-
Jim Cramer highlighted Incyte as a top S&P 500 winner on June 30, 2025.Speculative1 report
-
Incyte and Regeneron Pharmaceuticals are identified as major players in the immuno-oncology industry.Some support2 reports
-
Collaboration between Qiagen and Incyte to develop a novel diagnostic panel, leveraging FDA approvals for market access in the US.Speculative2 reports
-
Incyte granted equity awards to Bill Meury on July 3, 2025.Speculative1 report
-
Bridgewater Associates holds over $38 million worth of Incyte shares and maintains a 'Hold' rating on the stock.Speculative1 report
-
McKesson Corporation and Incyte reported positive Earnings Stock Purchase Plan (ESP) figures on July 10, 2025.Some support1 report
-
Incyte commercializes its therapeutics across Europe, Canada, and Japan, following a major market expansion announcement on July 11, 2025.Well supported5 reports
-
Incyte presented data at a congress held in Berlin, Europe on July 25, 2025.Some support2 reports
-
Incyte conducts European clinical development operations in Geneva.Some support2 reports
-
The FDA approved retifanlimab for MCC treatment, following an amended supply and distribution agreement between Incyte and Knight Therapeutics for use in Latin America.Some support1 report1 development inside
-
Christiana Stamoulis stepped down as CFO of Incyte, which aims to find solutions for patients.Some support1 report
-
Incyte and Natera are identified as peers within the biotechnology segment.Some support3 reports
-
Incyte is collaborating with Actuate Therapeutics and researchers at the University of Pittsburgh on a clinical trial targeting advanced pancreatic cancer.Some support1 report
-
Incyte received a stock rating upgrade and price target increase from an unnamed source, involving Wells Fargo.Some support1 report
-
Financial institutions including Goldman Sachs, Bank of America, and Mizuho Securities made inquiries regarding competitive positioning and activity related to povorcitinib and INCA033989.Some support2 reports1 development inside
-
Novartis markets Jakavi in ex-U.S. markets, leading to Incyte earning royalties and benefiting from FDA approval of Opzelura.Some support2 reports
-
The tariff plan caused market tanking, impacting companies like Saia and Incyte, and prompting investment analysis.Some support1 report1 development inside
-
Northern Trust details its history, founded in 1889 during Chicago's post-Great Fire rebuilding boom. Incyte is noted for evolving from a genomics research firm to a drug developer.Some support1 report
-
Soni Basi was appointed Chief Human Resources Officer at Incyte.Some support1 report
-
Qiagen and Incyte formed a partnership to develop a companion diagnostic for mutant calreticulin.Some support1 report
-
Increased patient demand and refills in the US for Incyte as of August 28, 2025.Some support1 report
No events began in the chosen period. Widen it, or reset.
What's reaching Incyte
Events traced to Incyte, step by step, newest firstAround Incyte this week
News at the entities that move Incyte most-
FDA StructuralLitigation regarding FDA approval process.Moves Incyte
-
SEC StructuralA company increased its holdings by 24.4% in Q1 and reported the transaction to the SEC.Moves Incyte
-
Securities and Exchange Commission StructuralA capital market conference was held in Abuja, Nigeria, and the Securities and Exchange Commission issued a statement on market targets.Moves Incyte
-
Syndax Pharmaceuticals OperationalSyndax Pharmaceuticals presented data at EHA Congress and is seeking successful regulatory approval for its drug pipeline.Moves Incyte
-
TD Cowen Mentioned togetherMultiple financial firms, including TD Cowen, Goldman Sachs, and Mizuho, issued various rating changes and price target updates across several stocks.Moves Incyte
-
Novartis StructuralSean Maenpaa, with experience at Novartis and Celgene, was appointed SVP Business Development at Clovis Oncology.Moves Incyte
Connections
The 40 strongest of 133, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Syndax Pharmaceuticals Operational
Syndax and Incyte maintain an exclusive worldwide co-development and co-commercialization partnership for the drug Niktimvo.
-
Qiagen Operational
Qiagen and Incyte maintain a strategic partnership focused on developing and supplying companion diagnostics for Incyte's targeted therapies.
-
FDA Structural
Incyte's drug pipeline and commercial success fundamentally depend on regulatory approvals and reviews provided by the FDA.
-
Halozyme Therapeutics Operational
The companies have established a global partnership to develop subcutaneous formulations of the drug candidate INCA033989.
-
SEC Structural
Incyte is structurally regulated by the SEC, requiring it to file specific financial reports like 13F filings.
-
Securities and Exchange Commission Structural
Incyte is structurally required to file share ownership disclosures mandated by the Securities and Exchange Commission.
-
Knight Therapeutics Structural
Knight Therapeutics holds exclusive distribution rights for Incyte's products, forming a co-development and supply partnership.
-
Fifth Third Bancorp Transactional
Fifth Third Bancorp is increasing its holdings/investment in Incyte stock.
Show all 40 connections
-
Leerink partners Transactional
Leerink partners increased its price objective regarding Incyte.
-
Cantor Fitzgerald Transactional
Cantor Fitzgerald issued and reaffirmed market ratings on Incyte shares.
-
TD Cowen Mentioned together
TD Cowen provides financial ratings and coverage for Incyte stock.
-
Novartis Structural
Novartis provides royalties to Incyte based on the commercialization and sales of Jakavi/Jakafi.
-
AbbVie Operational
Both companies are direct competitors in the biotechnology sector, specifically developing JAK inhibitors for alopecia.
-
Mirum Pharmaceuticals Operational
The two companies are actively collaborating on the PROGRESS study.
-
Morgan Stanley Mentioned together
Morgan Stanley provides market analysis and sets target prices for Incyte shares.
-
Agios Pharmaceuticals Operational
Agios Pharmaceuticals and Incyte are direct competitors in the healthcare sector, often compared on financial metrics.
-
Alvotech Operational
The two companies are identified as competitors within the healthcare market.
-
Goldman Sachs Mentioned together
Goldman Sachs provides financial analysis and coverage of Incyte's business and competitive positioning.
-
CMS Transactional
Incyte received a settlement benefit from CMS regarding its operations.
-
European Medicines Agency Structural
Incyte relies on the European Medicines Agency for regulatory approval of its pharmaceutical products.
-
Dover Transactional
A received funds/resources from B via a grant agreement, which was subsequently reduced.
-
Natera Operational
Incyte and Natera are peers and competitors operating within the immuno-oncology and biotechnology segments.
-
Stifel Mentioned together
Stifel provides financial analysis and ratings regarding Incyte's performance.
-
Biotech Mentioned together
Biotech is mentioned in the M&A context of Incyte.
-
Europe Shared context
Incyte maintains commercial and R&D operations within the European market.
-
Kras Operational
Both companies are actively competing in the development of inhibitors for PDAC.
-
European Academy of Dermatology and Venereology Operational
Incyte is scheduled to present scientific data at the European Academy of Dermatology and Venereology conference.
-
Wilmington Shared context
The company Incyte is headquartered in the city of Wilmington, Delaware.
-
Moderna Shared context
Both companies operate within the competitive biotechnology segment.
-
Norges Bank Transactional
Norges Bank purchased a new financial stake in Incyte on July 21, 2026.
-
Biogen Mentioned together
Both companies are co-mentioned as operating within the competitive biotechnology segment.
-
Josh Brown Mentioned together
Josh Brown publicly recommended Incyte stock as a best investment.
-
Citigroup Operational
Citigroup provided a market rating on Incyte stock.
-
MarketBeat Mentioned together
MarketBeat provides analyst recommendations regarding Incyte.
-
Sino Biopharmaceutical Limited Mentioned together
Both companies are described as large-cap medical companies.
-
Truist Financial Mentioned together
Truist Financial provided analyst coverage, including target price increases, for Incyte.
-
Nasdaq Shared context
Incyte is listed and trades on the Nasdaq stock exchange.
-
Royal Bank of Canada Mentioned together
RBC provided financial coverage by raising the price target and rating for Incyte stock.
-
Madrid Shared context
Incyte is scheduled to present data at the ESMO Congress held in Madrid.
-
State Street Mentioned together
The provided evidence does not describe a relationship between Incyte and State Street.
History
Events by the month they beganOctober 2026
2 eventsSeptember 2026
5 events- Incyte, a biotech company based in Wilmington, outperformed the biotech ETF.
- Incyte is presenting data at the European Academy of Dermatology and Venereology (EADV) conference held in Vienna.
- GSK, Incyte, Vertex, and Janssen announced new collaboration agreements with Halozyme on September 21, 2026.
- MarketBeat provided analyst recommendations for Incyte on September 20, 2026.
- Dr. Iyengar gained experience during his tenure, involving companies such as Incyte, Novartis, and McKinsey & Company.
August 2026
5 events- Truist Financial, Leerink partners, and Morgan Stanley have raised price targets and weighed in on Incyte stock.
- Incyte stock is trading on the Nasdaq exchange, with its performance being discussed in a bullish light due to strong fundamentals and earnings momentum.
- Wellington Management reduced its stock holdings in Incyte, alongside sales by EVP Patrick Mayes and insider Pablo Cagnoni.
- FDA approved Rasonque for metastatic PDAC, while Kras and Incyte also developed PDAC inhibitors and Incyte received a CMS settlement benefit.
- TD Cowen upgraded shares of Incyte to strong-buy rating and adjusted price targets on August 25, 2026.
Show 2 earlier months
July 2026
8 events- AbbVie, Incyte, and Biogen are noted as peers in the biotechnology segment after reporting their Q2 financial results.
- Incyte received a one-time accounting benefit from a CMS settlement.
- Citigroup provided a market rating on Incyte stock.
- Norges Bank purchased a new stake in Incyte, while RBC and TD Cowen provided stock rating updates on July 21, 2026.
- Governor Matt Meyer launched an initiative in Dover, which involved grant agreement reductions that subsequently freed up funds for the state of Delaware.
- Incyte filed required share ownership disclosure documents with the Securities and Exchange Commission on July 14, 2026.
- Incyte acquired Vega Therapeutics to diversify its late-stage pipeline.
- TD Cowen, Royal Bank of Canada, and Oppenheimer Holdings reaffirmed ratings and raised price targets for Incyte stock.
June 2026
36 events- Syndax Pharmaceuticals reported collaboration revenue derived from Niktimvo sales.
- FDA review extended for ruxolitinib cream, while Incyte benefits from potential Trump-era tariffs, leading to analyst upgrades and recommendations.
- Knight's affiliate submitted an application to ANVISA and secured exclusive distribution rights for Incyte's tafasitamab.
- Biotech M&A speculation involving Incyte, AbbVie, and Viking Therapeutics, with three Nasdaq-listed names under watch.
- Sino Biopharmaceutical Limited and Incyte are both classified as large-cap medical companies.
- The European Medicines Agency is seeking a positive opinion on ruxolitinib cream, with final approval resting with the executive branch.
- FDA accepted NDA for zilurgisertib in FOP, following collaboration on the PROGRESS study between Mirum Pharmaceuticals and Incyte.
- Stifel reiterated a Buy rating on Incyte.
- Incyte was required to file 13F filings with the SEC on June 6, 2026.
- Incyte appointed Bill Meury as the new CEO on June 27, 2025, causing the company's stock to rise.
- Bristol Myers Squibb and Incyte pioneered novel therapies for anal cancer.
- Incyte granted equity awards to Asia, tied to relative total shareholder return, on August 28, 2025.
- The FDA approved Niktimvo, Trump pledged benefits for oil and gas stocks, and several companies reported new HR hires.
- Incyte and Gilead Sciences are discussed in the context of commercializing innovative medicines for life-threatening diseases.
- Incyte's Opzelura received approval in the United States on June 23, 2025, and the FDA extended the review for the company's sNDA.
- Jim Cramer highlighted Incyte as a top S&P 500 winner on June 30, 2025.
- Incyte and Regeneron Pharmaceuticals are identified as major players in the immuno-oncology industry.
- Collaboration between Qiagen and Incyte to develop a novel diagnostic panel, leveraging FDA approvals for market access in the US.
- Incyte granted equity awards to Bill Meury on July 3, 2025.
- Bridgewater Associates holds over $38 million worth of Incyte shares and maintains a 'Hold' rating on the stock.
- McKesson Corporation and Incyte reported positive Earnings Stock Purchase Plan (ESP) figures on July 10, 2025.
- Incyte commercializes its therapeutics across Europe, Canada, and Japan, following a major market expansion announcement on July 11, 2025.
- Incyte presented data at a congress held in Berlin, Europe on July 25, 2025.
- Incyte conducts European clinical development operations in Geneva.
- The FDA approved retifanlimab for MCC treatment, following an amended supply and distribution agreement between Incyte and Knight Therapeutics for use in Latin America.
- Christiana Stamoulis stepped down as CFO of Incyte, which aims to find solutions for patients.
- Incyte and Natera are identified as peers within the biotechnology segment.
- Incyte is collaborating with Actuate Therapeutics and researchers at the University of Pittsburgh on a clinical trial targeting advanced pancreatic cancer.
- Incyte received a stock rating upgrade and price target increase from an unnamed source, involving Wells Fargo.
- Financial institutions including Goldman Sachs, Bank of America, and Mizuho Securities made inquiries regarding competitive positioning and activity related to povorcitinib and INCA033989.
- Novartis markets Jakavi in ex-U.S. markets, leading to Incyte earning royalties and benefiting from FDA approval of Opzelura.
- The tariff plan caused market tanking, impacting companies like Saia and Incyte, and prompting investment analysis.
- Northern Trust details its history, founded in 1889 during Chicago's post-Great Fire rebuilding boom. Incyte is noted for evolving from a genomics research firm to a drug developer.
- Soni Basi was appointed Chief Human Resources Officer at Incyte.
- Qiagen and Incyte formed a partnership to develop a companion diagnostic for mutant calreticulin.
- Increased patient demand and refills in the US for Incyte as of August 28, 2025.